Evidence map›Paper›PMID 36105321›Full record

ArticleDrug design, development and therapy2022

Levistilide a Induces Ferroptosis by Activating the Nrf2/HO-1 Signaling Pathway in Breast Cancer Cells.

Shangwen Jing, Yantong Lu, Jing Zhang, Yan Ren, Yousheng Mo, Dongdong Liu, Lining Duan, Zhongyu Yuan, Changjun Wang, Qi Wang

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. AAT-MSC-EVs: Novel implications for suppressing ferroptosis, fibrosis and pain associated with chronic pancreatitis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. The Mechanisms of Ferroptosis Under Hypoxia.Cellular and molecular neurobiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Shangwen Jing *Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Yantong Lu *Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Jing ZhangScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Yan RenScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Yousheng MoThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.ORCID 0000-0001-7599-6015
Dongdong LiuThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Lining DuanThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Zhongyu YuanDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
Changjun WangGuangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Geriatric Institute, Guangzhou, People's Republic of China.ORCID 0000-0003-0420-4679
Qi WangScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Guangzhou University of Chinese Medicine · CNFirst Affiliated Hospital of Guangzhou University of Chinese Medicine · CNGuangdong Academy of Medical Sciences · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Breast cancer (BC) is the leading female malignancy, with one million new cases diagnosed worldwide per year. However, the current treatment options for BC patients have difficulty achieving satisfactory efficacy. Ferroptosis is a new mode of regulated cell death that plays a key role in the inhibition of tumorigenesis. Levistilide A (LA), as an active compound extracted from Chuanxiong Rhizoma, might prevent the development of tumors by regulating the critical cellular processes of ferroptosis. Methods: In this study, the underlying mechanisms of LA on ferroptosis in BC were explored in vitro. The effect of LA on the viability and mitochondrial function of BC cells was determined. Moreover, the effect of LA on the expression levels of key molecules involved in ferroptosis and the nuclear factor erythroid-2-related factor 2/heme oxygenase 1 (Nrf2/HO-1) signaling pathway was evaluated. Results: LA significantly reduced cell viability and damaged the mitochondrial structure and function of BC cells in a dose-dependent manner. Furthermore, LA treatment markedly enhanced reactive oxygen species (ROS)-induced ferroptosis by activating the Nrf2/HO-1 signaling pathway. Conclusion: These findings suggest that LA may be a potential lead compound for breast cancer therapy by inducing ferroptosis in tumor cells.

Indexed as

Breast NeoplasmsFerroptosisFemaleHeme Oxygenase-1Heterocyclic Compounds, Bridged-RingHumansNF-E2-Related Factor 2Signal TransductionHeme Oxygenase-1Heterocyclic Compounds, Bridged-RingHMOX1 protein, humanlevistilide ANF-E2-Related Factor 2breast cancerferroptosislevistilide ANrf2/HO-1 signaling pathway

Identifiers

PMID36105321
PMCPMC9464640
OpenAlexW4294860875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.